Comment
doi: 10.1158/1078-0432.CCR-09-2256.
Epub 2009 Oct 27.
Enhancing cancer vaccine efficacy via modulation of the tumor microenvironment
Affiliations
- PMID: 19861446
- DOI: 10.1158/1078-0432.CCR-09-2256
Item in Clipboard
Comment
Enhancing cancer vaccine efficacy via modulation of the tumor microenvironment
Clin Cancer Res.
.
Abstract
The development of therapeutic cancer vaccines is impacted by immunosuppressive elements in the tumor microenvironment. Most immunogenic cancer proteins are "self," therefore, peripheral tolerance contributes substantially to tumor immune escape. Transforming growth factor beta (TGFbeta) actively modulates both inflammation and tolerance induction. Combining vaccination with agents that disarm TGFbeta will enhance vaccine efficacy.
Comment on
-
Synergistic enhancement of CD8+ T cell-mediated tumor vaccine efficacy by an anti-transforming growth factor-beta monoclonal antibody.Clin Cancer Res. 2009 Nov 1;15(21):6560-9. doi: 10.1158/1078-0432.CCR-09-1066. Epub 2009 Oct 27. Clin Cancer Res. 2009. PMID: 19861451 Free PMC article.
-
Systemic inhibition of transforming growth factor-beta in glioma-bearing mice improves the therapeutic efficacy of glioma-associated antigen peptide vaccines.Clin Cancer Res. 2009 Nov 1;15(21):6551-9. doi: 10.1158/1078-0432.CCR-09-1067. Epub 2009 Oct 27. Clin Cancer Res. 2009. PMID: 19861464 Free PMC article.
Similar articles
-
Leveraging the activity of tumor vaccines with cytotoxic chemotherapy.Cancer Res. 2005 Sep 15;65(18):8059-64. doi: 10.1158/0008-5472.CAN-05-1797. Cancer Res. 2005. PMID: 16166275 Review.
-
Myeloid-derived suppressor cell role in tumor-related inflammation.Cancer Lett. 2008 Aug 28;267(2):216-25. doi: 10.1016/j.canlet.2008.03.012. Epub 2008 Apr 22. Cancer Lett. 2008. PMID: 18433992 Review.
-
A possible "universal" cancer vaccine that might cause an immune response against emerging cancer cells that originate from any tissue.Med Hypotheses. 2008;70(2):381-3. doi: 10.1016/j.mehy.2007.04.040. Epub 2007 Jul 12. Med Hypotheses. 2008. PMID: 17629418
-
Inhibition of TGFbeta signaling in cancer therapy.Curr Opin Genet Dev. 2006 Feb;16(1):30-7. doi: 10.1016/j.gde.2005.12.009. Epub 2005 Dec 27. Curr Opin Genet Dev. 2006. PMID: 16377175 Review.
-
Immunosuppressive mechanisms in cancer: consequences for the development of therapeutic vaccines.Vaccine. 2009 May 26;27(25-26):3398-400. doi: 10.1016/j.vaccine.2009.01.070. Epub 2009 Feb 5. Vaccine. 2009. PMID: 19200836
Cited by
-
Rebalancing immune specificity and function in cancer by T-cell receptor gene therapy.Arch Immunol Ther Exp (Warsz). 2010 Oct;58(5):335-46. doi: 10.1007/s00005-010-0090-1. Epub 2010 Aug 1. Arch Immunol Ther Exp (Warsz). 2010. PMID: 20680493 Free PMC article. Review.
-
A combination trial of vaccine plus ipilimumab in metastatic castration-resistant prostate cancer patients: immune correlates.Cancer Immunol Immunother. 2014 Apr;63(4):407-18. doi: 10.1007/s00262-014-1524-0. Epub 2014 Feb 11. Cancer Immunol Immunother. 2014. PMID: 24514956 Free PMC article. Clinical Trial.
-
Intratumoral delivery of tumor antigen-loaded DC and tumor-primed CD4+ T cells combined with agonist α-GITR mAb promotes durable CD8+ T-cell-dependent antitumor immunity.Oncoimmunology. 2017 Apr 24;6(6):e1315487. doi: 10.1080/2162402X.2017.1315487. eCollection 2017. Oncoimmunology. 2017. PMID: 28680744 Free PMC article.
-
Targeting TGFβ signal transduction for cancer therapy.Signal Transduct Target Ther. 2021 Jan 8;6(1):8. doi: 10.1038/s41392-020-00436-9. Signal Transduct Target Ther. 2021. PMID: 33414388 Free PMC article. Review.
-
Recruitment of regulatory T cells is correlated with hypoxia-induced CXCR4 expression, and is associated with poor prognosis in basal-like breast cancers.Breast Cancer Res. 2011 Apr 26;13(2):R47. doi: 10.1186/bcr2869. Breast Cancer Res. 2011. PMID: 21521526 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
